Search research articles
Contact Us
Filters
Showing results (31-40 of 64) with videos related to
Page
of 7
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
August 5, 2023
Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis
Pauline Corbaux, Benoit You, Rosalind M Glasspool, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
November 19, 2025
Identifying high-risk relapse in early-stage I to II ovarian cancer using the CA125 ELIMination rate constant K (KELIM) score: a Gynecologic Cancer InterGroup individual patient-data meta-analysis
Pauline Corbaux, Benoit You, Tatsuo Kagimura, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 6, 2011
Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer
Jonathan A Ledermann, Christian Marth, Mark S Carey, et al.
Cancer Causes & Control : CCC
|
January 5, 2017
Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium
Ana Babic, Daniel W Cramer, Linda E Kelemen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 24, 2006
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor
Jennifer C C Hu, Robert S Coffin, Ceri J Davis, et al.
Current Biology : CB
|
March 8, 2016
The Initiator Methionine tRNA Drives Secretion of Type II Collagen from Stromal Fibroblasts to Promote Tumor Growth and Angiogenesis
Cassie J Clarke, Tracy J Berg, Joanna Birch, et al.
Chemotherapy
|
April 28, 2024
The Hammersmith Score Optimises Patient Selection and Predicts for Overall Survival in Early-Phase Cancer Trial Participants Independent of Tumour Burden
James Alexander Korolewicz, Bernhard Scheiner, Claudia A M Fulgenzi, et al.
EMBO Molecular Medicine
|
May 14, 2020
Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors
Álvaro Lahiguera, Petra Hyroššová, Agnès Figueras, et al.
Nature Communications
|
March 18, 2026
Multimodal imaging reveals a lysosomal drug reservoir that drives heterogeneous distribution of PARP inhibitors
Carmen R Moncayo, Restuadi Restuadi, Guanying Zhang, et al.
Cancers
|
January 21, 2023
British Gynaecological Cancer Society Recommendations for Evidence Based, Population Data Derived Quality Performance Indicators for Ovarian Cancer
Sudha Sundar, Andy Nordin, Jo Morrison, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 64) with videos related to
Sort By:
Page
of 7
European Journal of Cancer (Oxford, England : 1990)
|
August 5, 2023
Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis
Pauline Corbaux, Benoit You, Rosalind M Glasspool, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
November 19, 2025
Identifying high-risk relapse in early-stage I to II ovarian cancer using the CA125 ELIMination rate constant K (KELIM) score: a Gynecologic Cancer InterGroup individual patient-data meta-analysis
Pauline Corbaux, Benoit You, Tatsuo Kagimura, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 6, 2011
Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer
Jonathan A Ledermann, Christian Marth, Mark S Carey, et al.
Cancer Causes & Control : CCC
|
January 5, 2017
Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium
Ana Babic, Daniel W Cramer, Linda E Kelemen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 24, 2006
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor
Jennifer C C Hu, Robert S Coffin, Ceri J Davis, et al.
Current Biology : CB
|
March 8, 2016
The Initiator Methionine tRNA Drives Secretion of Type II Collagen from Stromal Fibroblasts to Promote Tumor Growth and Angiogenesis
Cassie J Clarke, Tracy J Berg, Joanna Birch, et al.
Chemotherapy
|
April 28, 2024
The Hammersmith Score Optimises Patient Selection and Predicts for Overall Survival in Early-Phase Cancer Trial Participants Independent of Tumour Burden
James Alexander Korolewicz, Bernhard Scheiner, Claudia A M Fulgenzi, et al.
EMBO Molecular Medicine
|
May 14, 2020
Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors
Álvaro Lahiguera, Petra Hyroššová, Agnès Figueras, et al.
Nature Communications
|
March 18, 2026
Multimodal imaging reveals a lysosomal drug reservoir that drives heterogeneous distribution of PARP inhibitors
Carmen R Moncayo, Restuadi Restuadi, Guanying Zhang, et al.
Cancers
|
January 21, 2023
British Gynaecological Cancer Society Recommendations for Evidence Based, Population Data Derived Quality Performance Indicators for Ovarian Cancer
Sudha Sundar, Andy Nordin, Jo Morrison, et al.
Page
of 7